Deutsch E - Search Results

1

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferté C. Sun R, et al. Among authors: deutsch e. Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18. Eur J Cancer. 2017. PMID: 28826073

2

Chemoprevention of lung cancer.

Soria JC, Kim ES, Fayette J, Lantuejoul S, Deutsch E, Hong WK. Soria JC, et al. Among authors: deutsch e. Lancet Oncol. 2003 Nov;4(11):659-69. doi: 10.1016/s1470-2045(03)01244-0. Lancet Oncol. 2003. PMID: 14602246 Review.

3

Tumour stem cell-targeted treatment: elimination or differentiation.

Massard C, Deutsch E, Soria JC. Massard C, et al. Among authors: deutsch e. Ann Oncol. 2006 Nov;17(11):1620-4. doi: 10.1093/annonc/mdl074. Epub 2006 May 3. Ann Oncol. 2006. PMID: 16600978 Free article. Review.

4

Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.

Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magné N, Pignon JP, Vassal G, Armand JP, Soria JC. Italiano A, et al. Among authors: deutsch e. Ann Oncol. 2008 Apr;19(4):787-92. doi: 10.1093/annonc/mdm548. Epub 2007 Nov 27. Ann Oncol. 2008. PMID: 18042834 Free article. Review.

5

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.

Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC. Loriot Y, et al. Among authors: deutsch e. Nat Clin Pract Oncol. 2008 May;5(5):268-78. doi: 10.1038/ncponc1087. Epub 2008 Mar 18. Nat Clin Pract Oncol. 2008. PMID: 18349858 Review.

6

The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.

Magné N, Chargari C, Castadot P, Ghalibafian M, Soria JC, Haie-Meder C, Bourhis J, Deutsch E. Magné N, et al. Among authors: deutsch e. Eur J Cancer. 2008 Oct;44(15):2133-43. doi: 10.1016/j.ejca.2008.06.029. Epub 2008 Aug 7. Eur J Cancer. 2008. PMID: 18692389 Review.

7

Concomitant chemo-radiotherapy in clinical trials: to promote step by step rational development.

Magné N, Chargari C, Soria JC, Deutsch E. Magné N, et al. Among authors: deutsch e. Crit Rev Oncol Hematol. 2009 Jun;70(3):206-15. doi: 10.1016/j.critrevonc.2008.09.016. Epub 2008 Nov 29. Crit Rev Oncol Hematol. 2009. PMID: 19042138 Review.

8

Are RAS mutations predictive markers of resistance to standard chemotherapy?

Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Loriot Y, et al. Among authors: deutsch e. Nat Rev Clin Oncol. 2009 Sep;6(9):528-34. doi: 10.1038/nrclinonc.2009.106. Epub 2009 Jul 14. Nat Rev Clin Oncol. 2009. PMID: 19597509 Review.

9

Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination.

Mordant P, Loriot Y, Leteur C, Calderaro J, Bourhis J, Wislez M, Soria JC, Deutsch E. Mordant P, et al. Among authors: deutsch e. Mol Cancer Ther. 2010 Feb;9(2):358-68. doi: 10.1158/1535-7163.MCT-09-1014. Epub 2010 Feb 2. Mol Cancer Ther. 2010. PMID: 20124452

10

[Anti-apoptotic mechanisms in small-cell lung carcinoma].

Loriot Y, Calderaro J, Soria JC, Deutsch E, Vielh P. Loriot Y, et al. Among authors: deutsch e. Ann Pathol. 2010 Feb;30(1):17-24. doi: 10.1016/j.annpat.2009.12.005. Epub 2010 Feb 20. Ann Pathol. 2010. PMID: 20223350 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,229 results

Search Page

Filters